Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents.

Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V; Definitions/Nomenclature Working Group* of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research.

Hepatology. 2012 Dec;56(6):2398-403. doi: 10.1002/hep.25888.

PMID:
22707382
2.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
3.

Hepatitis C virus viral assays in the direct-acting antiviral era.

Vierling JM.

Clin Liver Dis. 2013 Feb;17(1):27-45. doi: 10.1016/j.cld.2012.09.002. Review.

PMID:
23177281
4.

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2006 Jan;78(1):83-90.

PMID:
16299715
5.

Virological tools to diagnose and monitor hepatitis C virus infection.

Chevaliez S.

Clin Microbiol Infect. 2011 Feb;17(2):116-21. doi: 10.1111/j.1469-0691.2010.03418.x. Epub 2010 Dec 14. Review.

6.

Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations.

Jacobson IM, Poordad F, Brown RS Jr, Kwo PY, Reddy KR, Schiff E.

J Viral Hepat. 2012 Apr;19(4):236-43. doi: 10.1111/j.1365-2893.2011.01552.x. Epub 2011 Dec 2.

PMID:
22404721
7.

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

Seeff LB, Hoofnagle JH.

Clin Liver Dis. 2003 Feb;7(1):261-87. Review.

PMID:
12691470
8.

Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C.

Martinot M, Marcellin P, Boyer N, Detmer J, Pouteau M, Castelnau C, Degott C, Aupérin A, Collins M, Kolberg J, Wilber J, Benhamou JP, Erlinger S.

Ann Intern Med. 1997 Jun 1;126(11):874-81.

PMID:
9163288
9.

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.

El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, Hotta H.

Microbiol Immunol. 2011 Jun;55(6):418-26. doi: 10.1111/j.1348-0421.2011.00331.x.

10.

Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.

Lee C.

Arch Pharm Res. 2011 Sep;34(9):1403-7. doi: 10.1007/s12272-011-0921-6. Review.

PMID:
21975800
11.

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intervirology. 2005;48(6):372-80.

PMID:
16024941
12.
13.

Pathogenesis, diagnosis and management of hepatitis C.

Boyer N, Marcellin P.

J Hepatol. 2000;32(1 Suppl):98-112. Review.

PMID:
10728798
15.

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR.

Liver Transpl. 2004 Feb;10(2):199-207.

16.

Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.

Mancini N, Carletti S, Perotti M, Romanò L, Craxì RD, Craxì A, Zanetti AR, Clementi M, Burioni R.

J Med Virol. 2006 Oct;78(10):1304-11.

PMID:
16927283
17.

Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection.

Fernández I, Castellano G, Domingo MJ, Fuertes A, Colina F, Canga F, de la Cruz FJ, de la Cámara AG, Solís JA.

Scand J Gastroenterol. 1997 Jan;32(1):70-6.

PMID:
9018770
18.

Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration.

Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G.

J Clin Virol. 2011 Dec;52(4):367-9. doi: 10.1016/j.jcv.2011.08.020. Epub 2011 Sep 15.

PMID:
21924673
19.

Patterns of hepatitis C viremia in patients receiving hemodialysis.

Umlauft F, Gruenewald K, Weiss G, Kessler H, Urbanek M, Haun M, Santner B, Koenig P, Keeffe EB.

Am J Gastroenterol. 1997 Jan;92(1):73-8.

PMID:
8995941
20.

The role of insulin resistance in HIV/hepatitis C virus-coinfected patients.

Eslam M, López-Cortés LF, Romero-Gomez M.

Curr Opin HIV AIDS. 2011 Nov;6(6):553-8. doi: 10.1097/COH.0b013e32834bd21d. Review.

PMID:
21934619

Supplemental Content

Support Center